Advertisement
Product › Details
CliniMACS Prodigy® Adherent Cell Culture System
Next higher product group | cell culture system_o | |
Status | 2020-07-14 sales start | |
Organisation | Miltenyi Biotec B.V. & Co. KG | |
Group | Miltenyi Biotec (Group) | |
Miltenyi Biotec B.V. & Co. KG. (7/14/20). "Press Release: Miltenyi Biotec Offers Automated and Closed Adherent Cell Culture Solutions on CliniMACS Prodigy". Bergisch Gladbach.
End-to-end automatic cultivation of adherent stem cells and derivatives from a single instrument
Miltenyi Biotec announced the immediate availability of its new CliniMACS Prodigy® Adherent Cell Culture System. A flexible architecture specifically developed for the GMP-compliant CliniMACS Prodigy Platform, it enables the automated, scalable, and closed manufacturing of various adherent cell types, including stem cells and their derivatives. Tested processes include, for example, GMP-compliant expansion of human mesenchymal stromal cells, and pluripotent stem cells, as well as differentiation of the latter into dopaminergic progenitors.
The CliniMACS Prodigy Adherent Cell Culture System’s modular nature allows users to build customized and automated manufacturing processes suitable for the culture of adherent cell types in a closed system and a single instrument. This minimizes operator influences and open handling steps, thus increasing product consistency. Meanwhile, it reduces the requirements for high-class cleanroom facilities and manual operations, which represents significant cost savings on cleanroom operations and labor hours. Taken together, the CliniMACS Prodigy Adherent Cell Culture System is capable of meeting the various demands of regenerative medicine, in particular for reliable and cost-effective cell manufacturing to ultimately support cell therapies.
Regenerative medicine has become a key focus of labs and clinics worldwide, and the number of clinical trials using stem cells – especially pluripotent stem cells – is increasing rapidly every year.
Dr. Andreas Bosio, Senior R&D Manager at Miltenyi Biotec commented: “We have learned a lot from cell therapies using hematopoietic stem cells, and more recently CAR-T cells, and are now ready to transfer this knowledge to pluripotent stem cell–based therapies. This system enables routine production of small phase I batches up to mass production of thousands of doses in a ballroom approach. Moreover, the system is flexible enough to be used for experimental optimization of early-stage manufacturing protocols, for example, for new cell types.”
Prof. Dr. Annelise Bennaceur-Griscelli, University Paris Saclay, APHP– CITHERA Inserm UMR 935, found the CliniMACS Prodigy provided a safe and standardized, scalable manufacturing platform for GMP-iPSC master cell banks when using it to provide automated cell feeding and harvesting in a closed system.
The CliniMACS Prodigy Adherent Cell Culture System offers nine modules that automate different workflow steps required for expansion and differentiation of adherent cell types. Flexible combination of these modules, together with full control of the manufacturing parameters, allow for individual, customizable manufacturing workflows to suit a large variety of applications. Cell manufacturing takes place in the fully closed and GMP-compliant CliniMACS Prodigy Tubing Set 730, whilst external culture vessels can be easily connected to bring cell manufacturing to larger scale.
Modules of the CliniMACS Prodigy Adherent Cell Culture System
Pre-process
Preparation of the system for all subsequent cell culture steps
Density gradient
Density gradient centrifugation of primary cell material
Coating
Coating of the CliniMACS Prodigy chamber or external culture vessels (ECVs)
Inoculation
Seeding of cells in the CliniMACS Prodigy chamber or ECVs
Culture
Cell cultivations in the CliniMACS Prodigy chamber
Media change
Media change in the CliniMACS Prodigy chamber or ECVs
Harvest
Harvest and formulation of the final cell product
Deinstallation
Guided step-by-step deinstallation of the tubing set
End
Completion of the process
For further information on the CliniMACS Prodigy® Adherent Cell Culture System and its modules click here.
About Miltenyi Biotec:
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy, from basic and translational research to clinical application. With over 3,000 employees in 28 countries Miltenyi Biotec is dedicated advancing biomedical sciences and developing novel therapies for unmet clinical needs.
www.miltenyibiotec.com
Media Contact:
Miltenyi Biotec B.V. & Co. KG
James Hafseth
press@miltenyibiotec.de
Record changed: 2023-07-10 |
Advertisement
More documents for cell culture system_o
- [1] Solentim Ltd.. (10/8/19). "Press Release: Mark Stockdale Joins Solentim in New »Amalgamator of Business and Biology« Position". Bournemouth....
- [2] Solentim Ltd.. (10/1/19). "Press Release: Dr Mark Truesdale Joins Solentim as New Chief Marketing Officer". Bournemouth....
- [3] Solentim Ltd.. (1/14/19). "Press Release: Solentim and ATUM Announce Technology Collaboration to Enable Rapid, High Expression, Stable Cell Line Development". Bournemouth....
- [4] Bioké (Cell Signaling Technology Europe B.V.). (1/14/19). "Press Release: Bioké and OLS Omni Life Science Announce a Distribution Agreement for the BeNeLux Countries". Leiden....
- [5] OLS Omni Life Science GmbH & Co. KG. (10/18/18). "Press Release: CERO Is a Novel 3D Cell Cultivation System". Bremen....
- [6] Lonza Group AG. (2/12/18). "Press Release: Lonza Expands Cell-Culture Portfolio with Quasi Vivo System". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top